US Patent

US11903953 — Remdesivir treatment methods

Method of Use · Assigned to Gilead Sciences Inc · Expires 2041-05-28 · 15y remaining

Vulnerability score 58/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects methods of treating or preventing a viral infection in a subject by administering a compound, excluding those treated with chloroquine.

USPTO Abstract

Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3833 — Veklury
U-3835 — Veklury

Patent Metadata

Patent number
US11903953
Jurisdiction
US
Classification
Method of Use
Expires
2041-05-28
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.